Your session is about to expire
← Back to Search
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide for Acute Leukemia (1703/1801 Trial)
1703/1801 Trial Summary
This trial is comparing two ways to prevent GVHD, a complication of stem cell transplants. One group will receive tacrolimus/methotrexate and the other group will receive post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil. The trial will also test the hypothesis that the engraftment stool microbiome diversity predicts one-year non-relapse mortality.
- Acute Leukemia
- Leukemia
- Myelodysplasia
- Lymphoma
1703/1801 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 431 Patients • NCT039592411703/1801 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this trial being run in a considerable number of hospitals throughout the nation?
"Currently, there are 39 different sites recruiting patients for this study. The locations of these centres include Cleveland, Seattle and Charleston. To reduce the amount of travelling required, it is best to choose a location near you."
How many individuals are taking part in this experiment?
"This study is not enrolling new patients at this time. The trial was first posted on June 25th, 2019 and last updated on November 10th, 20202. There are currently 3088 other trials actively recruiting participants with myelodysplasia and 1109 trials for Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide that are also looking for candidates."
Does the FDA sanction using Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide?
"This Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide has received a 3 for safety. This is due to the fact that it is a Phase 3 trial, and thus there is some evidence of efficacy as well as multiple rounds of data affirming its safety."
Are there other ongoing medical trials that are using a similar treatment to MPBSTC with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide?
"The first study investigating the use of Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide was conducted in 1997 at City of Hope Comprehensive Cancer Center. Since that time, there have been 2126 completed studies and 1109 active clinical trials worldwide--many of which are enrolling patients in Cleveland, Ohio."
How can people sign up for this research opportunity?
"Unfortunately, this study is no longer seeking new patients. The trial was first posted on June 25th, 2019 and last updated on November 10th, 2022. However, there are 3088 other studies actively recruiting patients with myelodysplasia and 1109 trials for Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide that may be of interest."
What is the standard procedure for Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide?
"Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide can be used to treat small cell lung cancer (sclc), dermatitis, atopic, and multiple sclerosis."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger